CALC (CalciMedica) Short Interest


CALC CalciMedica Inc CALC
23 GF Score
Price $0.59
! 2 Warning Signs
View Full Analysis

What is CalciMedica Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CALC vs TOVX, PHIO, PHGE: Short Interest Comparison

For the Biotechnology subindustry, CalciMedica's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CalciMedica Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CalciMedica's Short Interest distribution charts can be found below:

* The bar in red indicates where CalciMedica's Short Interest falls into.


CALC
23GF Score
CalciMedica Inc CALC
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CalciMedica Business Description

Address 505 Coast Boulevard South, Suite 307, La Jolla, CA, USA, 92037
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
23GF Score

Get the complete analysis for CALC

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.59
Price